S100A9 and myelodysplastic syndrome: Additionally, elevated expression of CD33 on MDSCs in MDS patients has been observed compared to healthy individuals; the interaction between S100A9 and CD33 on MDSCs facilitates their expansion within the bone marrow, creating a self-perpetuating cycle that exacerbates innate immune responses and drives disease progression [25].